TransMedics Group’s (TMDX) “Hold” Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of TransMedics Group (NASDAQ:TMDX) in a report issued on Friday morning, MarketBeat Ratings reports. The firm currently has a $109.00 price objective on the stock.

TMDX has been the subject of a number of other reports. Oppenheimer decreased their price objective on TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a report on Tuesday, October 29th. Baird R W raised TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Stephens increased their price objective on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. TD Cowen decreased their price objective on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a report on Monday, November 18th. Finally, Piper Sandler decreased their price objective on TransMedics Group from $180.00 to $110.00 and set an “overweight” rating for the company in a report on Wednesday. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, TransMedics Group has an average rating of “Moderate Buy” and a consensus price target of $131.80.

TransMedics Group Stock Down 4.2 %

Shares of TransMedics Group stock opened at $76.04 on Friday. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The business’s 50 day simple moving average is $120.68 and its 200-day simple moving average is $138.09. The stock has a market capitalization of $2.55 billion, a price-to-earnings ratio of 80.89 and a beta of 2.08. TransMedics Group has a twelve month low of $67.77 and a twelve month high of $177.37.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The company had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm’s revenue for the quarter was up 63.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.12) earnings per share. Equities research analysts forecast that TransMedics Group will post 1 earnings per share for the current year.

Insider Activity

In other news, Director Edward M. Basile sold 6,750 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the sale, the director now owns 732 shares in the company, valued at $61,158.60. This represents a 90.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Tamer I. Khayal sold 2,958 shares of the stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total value of $438,493.92. Following the completion of the sale, the insider now owns 20,843 shares of the company’s stock, valued at $3,089,766.32. The trade was a 12.43 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,958 shares of company stock worth $5,230,528. Insiders own 7.00% of the company’s stock.

Institutional Trading of TransMedics Group

A number of hedge funds have recently modified their holdings of TMDX. Russell Investments Group Ltd. lifted its holdings in shares of TransMedics Group by 337,462.5% in the first quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company’s stock valued at $1,997,000 after purchasing an additional 26,997 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its holdings in shares of TransMedics Group by 8.6% in the first quarter. State Board of Administration of Florida Retirement System now owns 9,843 shares of the company’s stock valued at $745,000 after purchasing an additional 780 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of TransMedics Group by 1.3% in the first quarter. Vanguard Group Inc. now owns 1,889,094 shares of the company’s stock valued at $139,680,000 after purchasing an additional 23,979 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of TransMedics Group by 8.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 297,324 shares of the company’s stock worth $21,985,000 after acquiring an additional 22,223 shares in the last quarter. Finally, Public Employees Retirement System of Ohio purchased a new stake in shares of TransMedics Group during the first quarter worth $1,588,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.